Dr. Martens (LON:DOCS) Stock: Insider Ije Nwokori Purchases 238 Shares

Dr. Martens plc (LON:DOCS) insider Ije Nwokori acquired 238 shares of Dr. Martens stock in a transaction on Wednesday, November 11th. The stock was acquired at an average cost of GBX 63 per share, for a total transaction of £149.94.

Ije Nwokori also recently made the following trade(s):

• On Friday, October 16th, Ije Nwokori sold 209,160 shares of Dr. Martens stock. The stock was sold at an average price of GBX 69, for a total value of £144,320.40.
• On Monday, October 12th, Ije Nwokori bought 220 shares of Dr. Martens stock. The stock was acquired at an average price of GBX 68 per share, with a total value of £149.60.
• On Friday, September 11th, Ije Nwokori bought 232 shares of Dr. Martens stock. The stock was acquired at an average price of GBX 65 per share, with a total value of £150.80.

Dr. Martens Stock Performance

Dr. Martens stock opened at GBX 53.10 on Thursday. The stock has a 50-day simple moving average of GBX 67.13 and a 200 day simple moving average of GBX 69.53. The company has a quick ratio of 1.13, a current ratio of 2.61 and a debt-to-equity ratio of 108.85. Dr. Martens plc has a 12-month low of GBX 52.10 and a 12-month high of GBX 90. The stock has a market capitalization of £508.31 million, a price-to-earnings ratio of 22.12, a P/E/G ratio of 6.40 and a beta of 0.26.

Dr. Martens (LON:DOCS) last posted its quarterly earnings data on Thursday, November 12th. The company reported GBX (1) earnings per share for the quarter. The company had revenue of £290.40 million during the quarter. Dr. Martens had a net margin of 3.11% and a return on equity of 6.89%. On average, research analysts anticipate that Dr. Martens plc will post 2.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Berenberg Bank reissued a “buy” rating and set a GBX 110 price target on shares of Dr. Martens in a research note on Friday, October 9th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of GBX 105.

Dr. Martens Company Profile

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot – named after the date it was produced – rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, “Docs” or “DM’s” were later adopted by musicians and subcultural pioneers who took them from the street to the global stage. Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.